Search
  • kelly1839

Advancing Health Equity in Clinical Trials

People from different ages, races and ethnicities can react differently to certain medical products. So, it follows that ensuring people from diverse backgrounds join clinical trials is essential to advancing health equity.


Although 40% of the U.S. population is made up of people from diverse ethnic and cultural backgrounds – and are disproportionally impacted by chronic conditions, they are incredibly under-represented in clinical research trials.


These current gaps in care exacerbate existing health challenges by curbing access to life-changing and life-saving treatments and limit insights into how different groups respond to new therapies.


Although some steps are being taken to help improve equity in clinical trials, there is still much work to be done. Additionally, there is also unequal representation in those who develop and design the clinical trials themselves.


Insight Clinical Trials is committed to advancing health equity in clinical trials

research. We are dedicated to safe research specializing in mental health conditions such as depression, anxiety, ADHD, Alzheimer’s disease, dementia and other neurological disorders.


Historically, researchers have not done a good job in making it clear to patients or participants exactly what is needed from them. It is important that participants of color understand exactly how important participation in clinical trials research is to them and their communities. The Insight Clinical Trials team communicates exactly what is involved in each clinical trial. Participants are informed on what they need to do, and the risks and benefits involved.


"Less than 5% of clinical trials participants are Hispanic." - Latino USA

"Less than 8% of participants are black." Drug Trials Snapshots | FDA

"In cardio trials less than 2.5% of participants are black" 2015-2016 Global Participation in Clinical Trials Report (fda.gov)


If we don’t include all ethnicities and racial groups, we won’t know if the trial drugs are

effective for all individuals and we will be missing the biggest patient population that could potentially benefit from treatment.


If you, someone you know, or a group which you are a member are interested in learning more about clinical trials, please call Elisa at 216-526-1843.


Source: https://www.fda.gov/consumers/minority-health-and-health-equity/clinical-trial-diversity

15 views0 comments